International Journal of Oral & Maxillofacial Surgery
Volume 39, Issue 3 , Pages 197-207 , March 2010

Clinical use of botulinum toxins in oral and maxillofacial surgery

  • O.W. Majid

      Affiliations

    • Corresponding Author InformationAddress: O.W. Majid, Department of Oral and Maxillofacial Surgery, College of Dentistry, University of Mosul, Mosul, Iraq.

,Accepted 30 October 2009.

References 

  1. Acquadro M, Borodic GE. Treatment of myofascial pain with botulinum toxin. Anesthesiology. 1994;80:705–706
  2. Adler C. Perioperative Use Of Botulinum Toxins. Abstracts Toxins 2008; Toxicon 51: 44.
  3. Alster T, Lupton J. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg. 2003;29:516–518
  4. Alvarez M, Grogan P: Efficacy and safety of Myobloc in headache prophylaxis: A retrospective observation. Abstracts Toxins 2008/Toxicon 51: p. 44.
  5. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(suppl 5):21–29
  6. Aquilina P, Vickers R, Mckellar G. Reduction of a chronic bilateral temporomandibular joint dislocation with intermaxillary fixation and botulinum toxin A. Br J Oral and Maxillofac Surg. 2004;42:272–273
  7. Armstrong MW, Mountain RE, Murray JA. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy. Clin Otolaryngol Allied Sci. 1996;21:15–20
  8. Arnaud S, Batifor D, Goudot P. Nonsurgical management of traumatic injuries of the parotid gland and duct using type A botulinum toxin. Plast Reconstr Surg. 2006;117:2426–2430
  9. Bakke M, Møller E, Werdelin LM, Dalager T, Kitai N. Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:693–700
  10. Bakke M, Werdelin LM, Dalager T, Fuglsang-Frederiksen A, Prytz S, Møller E. Reduced jaw opening from paradoxical activity of mandibular elevator muscles treated with botulinum toxin. Eur J Neurol. 2003;10:695–699
  11. Baumann L, Stezinger A, Vujevich J, Halem M, Bryde J, Black L. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: A double-blinded, placebo- controlled trial. Dermatol Surg. 2003;29:508–515
  12. Bentsianov B, Francis A, Blitzer A. Botulinum toxin treatment of temporomandibular disorders, masseteric hypertrophy, and cosmetic masseter reduction. Oper Tech Otolaryngol Head Neck Surg. 2004;15:110–113
  13. Blitzer A, Binder WJ, Aviv JE. The management of hyperfunctional facial lines with botulinum toxin: A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg. 1997;123:389–392
  14. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol. 1989;98:93–97
  15. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope. 2001;111:218–226
  16. Boghen D, Flanders M. Effectiveness of botulinum toxin in the treatment of spasmodic torticollis. Eur Neurol. 1993;33:199–203
  17. Borodic G, Acquadro M. Management of facial pain with botulinum toxin in a tertiary pain clinic. Naunyn Schmiedebergs Arch Phannacol. 2002;365(Suppl 2):R14
  18. Borodic GE, Acquadro MA. The Use of Botulinum Toxin for the Treatment of Chronic Facial Pain. J Pain. 2002;3:21–27
  19. Borodic GE, Pearce LB, Cheney M. Botulinum A toxin for treatment of aberrant facial nerve regeneration. Plast Reconstr Surg. 1993;91:1042–1045
  20. Botox Package Insert. Irvine, CA, Allergan, Inc.
  21. Brandt FS, Bellman B. Cosmetic use of botulinum toxin Aexotoxin for the aging neck. Dermatol Surg. 1998;24:1232–1234
  22. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53:1439–1446
  23. Brin MF. Botulinum toxin therapy: basic science and overview of other therapeutic applications. In:  Blitzer A editors. Management of facial lines and wrinkles. Philadelphia: Lippincott, Williams and Wilkins; 2000 p;p. 279–302
  24. Brin MF, Blitzer A, Herman S. Orofaciomandibular and lingual dystonia. In:  Moore AP editors. Handbook of Botulinim Toxin Treatment. Oxford, England: Blackwell Scientific; 1995;p. 151–163
  25. Brin MF, Blitzer A, Herman S. Oromandibular dystonia: Treatment of 96 patients with botulinum toxin. In:  Jankovic J,  Hallett M editor. Therapy With Botulinum Toxin.. New York, NY: Marcel Dekker; 1994;p. 429–435
  26. Brin MF, Fahn S, Moskowitz C. Localized injections of botulinum toxin for the treatment of focal dystonias and hemifacial spasm. Mov Disord. 1987;2:237–254
  27. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53:1431–1438
  28. Bulstrode NW, Harrison DH. The phenomenon of the late recovered Bell's palsy: treatment options to improve facial symmetry. Plast Reconstr Surg. 2005;115:1466–1471
  29. Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands. Med Hypotheses. 1997;48:337–339
  30. Capaccio P, Cuccarini V, Benicchio V. Treatment of iatrogenic submandibular sialocele with botulinum toxin. Case report. Br J Oral Maxillofac Surg. 2007;45:415–417
  31. Capaccio P, Paglia M, Minorati D, et al. Diagnosis and therapeutic management of iatrogenic parotid sialocele. Ann Otol Rhinol Laryngol. 2004;113:562–564
  32. Capaccio P, Torretta S, Osio M, Minorati D. Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders. Am J Otol – Head and Neck Medicine and Surgery. 2008;29:333–338
  33. Carruthers A, Carruthers J. Botulinum toxin type A: History and current cosmetic use in the upper face. Semin Cutan Med Surg. 2001;20:71–84
  34. Carruthers A: Facial aesthetic enhancement educational initiative. Chicago, IL, Faculty Training, July 2001; 13-15.
  35. Carruthers J, Carruthers A. The evolution of botulinum neurotoxin type A for cosmetic applications. J Cosmet Laser Ther. 2007;9:186–193
  36. Carruthers J, Carruthers A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21
  37. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840–849
  38. Carruthers SJ, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114(6 Suppl):1S–22S
  39. Cather JC, Cather JC, Menter A. Update on botulinum toxin for facial aesthetics. Dermatol Clin. 2002;20:749–761
  40. Charles PD, Davis TL, Shannon KM, Hook MA, Warner JS. Tongue protrusion dystonia: treatment with botulinum toxin. South Med J. 1997;90:522–525
  41. Cherington M. Botulism: update and review. Semin Neurol. 2004;24:155–163
  42. Chua CN, Quhill F, Jones E. Treatment of aberrant facial nerve regeneration with botulinum toxin A. Orbit. 2004;23:213–218
  43. Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg. 2005;115:573–574
  44. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423–1429
  45. Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type A botulinum toxin. Int J Oral Maxillofac Surg. 1997;26:458–460
  46. David A, Sherris M, Holger G. Botulinum toxin to minimize facial scarring. Facial Plast Surg. 2002;18:35–39
  47. De Almeida AT, Marques E, De Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No.):S37–S43
  48. De Bont LG, Stegenga B. Pathology of temporomandibular joint internal derangement and osteoarthrosis. Int J Oral Maxillofac Surg. 1993;22:71–74
  49. De Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type Apoisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200–3205
  50. Dembek ZF, Smith LA, Rusnak JM. Botulinum Toxin (chapter 16). In:  Dembek ZF editors. Medical Aspects of Biological Warfare. Virginia: Office of The Surgeon General; 2007;p. 337–353
  51. Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasoundguided versus blind intraparotid injections of botulinum toxin- A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg. 2004;106:93–96
  52. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003;49:34–38
  53. Dressler D, Mander GJ, Fink K. Equivalent potency of Xeomin and BOTOX. Abstracts Toxins 2008/Toxicon 51: 10.
  54. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol Stockh. 1995;115:459–461
  55. Drummond P. Mechanism of gustatory flushing in Frey's syndrome. Clin Auton Res. 2002;12:144–146
  56. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35–42
  57. Dworkin SF. A model for pain mechanisms in myogenous temporomandibular disorders. Pain Forum. 1997;6:166–169
  58. Dworkin SF, Leresche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord Facial Oral Pain 6:301-55. 1992;
  59. Ellies M, Gottstein U, Rohrbach-Volland S. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope. 2004;114:1856–1860
  60. Ellies M, Laskawi R, Gotz W. Immunohistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat. Eur Arch Otorhinolaryngol. 1999;256:148–152
  61. Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-todate report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg. 2003;61:454–457
  62. Ellies M, Laskawi R, Rohrbach-Volland S. Botulinum toxin to reduce saliva flow: Selected indications for ultrasound guided toxin application into salivary glands. Laryngoscope. 2002;112:82–86
  63. Ellies M, Laskawi R, Tormahlen G. The effect of local injection of botulinum toxin A on the parotid gland of the rat: An immunohistochemical and morphometric study. J Oral Maxillofac Surg. 2000;58:1251–1256
  64. Ellis MF, Daniell M. An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis. Clin Exp Ophthalmol. 2001;29:394–399
  65. Elston JS. Botulinum toxin A in clinical medicine. J Physiol (Paris). 1990;84:285–289
  66. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison”. Neurology. 1999;53:1850–1853
  67. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine—a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24:838–843
  68. Fagien S, Brandt FS. Primary and adjunctive use of botulinum toxin type A (Botox) in facial aesthetic surgery: beyond the glabella. Clin Plast Surg. 2001;28:127–148
  69. Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: A double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33(1 Spec No.):S2–S9
  70. Flynn TC. Myobloc. Dermatol Clin. 2004;22:207–211
  71. Flynn TC. Update on botulinum toxin. Semin Cutan Med Surg. 2006;25:115–121
  72. Flynn TC, Carruthers J, Carruthers A. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg. 2001;27:703–708
  73. Flynn TC, Clark RE. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg. 2003;29:519–522
  74. Foran P, Mohammed N, Lisk G. Evaluation of the therapeutic usefulness of botulinum neurotoxins B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2003;278:1363–1371
  75. Frampton JE, Easthope SE. Botulinum toxin A (Botox cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003;4:709–725
  76. Franz DR, Pitt LM, Clayton MA, Hanes MA, Rose KJ. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In:  DasGupta BR editors. Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York, NY: Plenum Press; 1993;p. 473–476
  77. Freeman SR, Cohen JL. New Neurotoxins on the Horizon. Aesthetic Surg J. 2008;28:325–330
  78. Freund B, Schwartz M. Intramuscular injection of botulinum toxin as an adjunct to arthrocentesis of the temporomandibular joint: preliminary observations. Br J Oral Maxillofac Surg. 2003;41:351–352
  79. Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain. 2003;4:159–165
  80. Freund B, Schwartz M, Symington JM. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral and Maxillofac Surg. 2000;38:466–471
  81. Freund B, Schwartz M, Symington JM. The Use of Botulinum Toxin for the Treatment of Temporomandibular Disorders: Preliminary Findings. J Oral Maxillofac Surg. 1999;57:916–920
  82. Freund BJ, Schwartz M. The use of botulinum toxin for the treatment of temporomandibular disorder. Oral Health. 1998;88:32–37
  83. Freund BJ, Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache. 2002;42:1033–1037
  84. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study. Headache. 2000;40:231–236
  85. Frost De , Kendell BD. Part II. The use of arthrocentesis for treatment of temporomandibular joint disorders. J Oral Maxillofac Surg. 1999;57:583–587
  86. Giess R, Naumann M, Werner E. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:121–123
  87. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982;46:86–94
  88. Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: Results of a randomized, blinded, vehicle-controlled study. Dermatol Surg. 2007;33(1 Spec No.):S76–S80
  89. Gusek-Schneider GC, Erbguth F. Protective ptosis by botulinum A toxin injection in corneal affectations. Klin Monatsbl Augenheilkd. 1998;213:15–22
  90. Hallett M. One man's poison—Clinical applications of botulinum toxin. N Engl J Med. 1999;341:118–120
  91. Halpern JL, Smith LA, Seamon KB, Groover KA, Habig WH. Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody. Infect Immun. 1989;57:18–22
  92. Hatheway CL. Clostridium botulinum and other clostridia that produce botulinum neurotoxins. In:  Hauschild AHW,  Dodds KL editor. Clostridium botulinum—Ecology and Control in Foods. New York, NY: Marcel Dekker, Inc; 1992;p. 3–10
  93. Hegedus F, Diecidue R, Taub D, Nyirady J. Non-surgical treatment modalities of facial photodamage: practical knowledge for the oral and maxillofacial professional. Int. J. Oral Maxillofac. Surg. 2006;35:389–398
  94. Hennings JMH, Krause E, Bötzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: Case report and review of the literature. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2008;32:1167–1171
  95. Hermanowicz N, Truong DD. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope. 1991;101:1216–1218
  96. Herrero BA, Ecklung AE, Streett CS, Ford DF, King JK. Experimental botulism in monkeys—Aclinical pathological study. Exp Mol Pathol. 1967;6:84–95
  97. Hofmann RJ. Treatment of Frey's syndrome (gustatory sweating) and ‘crocodile tears’ (gustatory epiphora) with purified botulinum toxin. Ophthalmic Plast Reconstr Surg. 2000;16:289–291
  98. Hogan P, Charles D, Watts MW, Massey JM. Severity and Impact of Xerostomia in Patients Treated with Botulinum Toxin Type B for Cervical Dystonia: Observations on the Quality of Life of Patients with Xerostomia. Curr Ther Res Clin Exp. 2004;65:161–171
  99. Holmes JM, Beck RW, Kip KE, Droste PJ, Leske DA. Botulinum toxin treatment versus conservative management in the acute traumatic sixth nerve palsy or paresis. J AAPOS. 2000;4:145–149
  100. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000;43(2 Pt 1):249–259
  101. Stefan KA, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:e1–e11
  102. Ing EB, Sullivan TJ, Clarke MP, Buncic JR. Oculomotor nerve palsies in children. J Pediatr Ophthalmol Strabismus. 1992;29:331–336
  103. Isaac AM. Unilateral temporalis muscle hypertrophy managed with botulinum toxin type A. Br J Oral Maxillofac Surg. 2000;38:571–572
  104. Ivanhoe CB, Lai JM, Francisco GE. Bruxism after brain injury: successful treatment with botulinum toxin- A. Arch Phys Med Rehabil. 1997;78:1272–1273
  105. Jankovic J, Orman J. Botulinum A toxin for cranial–cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616–623
  106. Jongerius PH, Van Den Hoogen F, Van Limbeek J, Gabreëls FJ, Van Hulst K, Rotteveel JJ. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics. 2004;114:620–627
  107. Jost Wh , Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs. 2007;67:669–683
  108. Kane MA. Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg. 1999;103:656–663
  109. Kerr NC, Hoehn MB. Botulinum toxin for sixth nerve palsies in children with brain tumors. J AAPOS. 2001;5:21–25
  110. Krohel GB, Cipollo CI, Gadipatti K. Contralateral botulinum toxin injections improve drinking ability and facial symmetry in patients with facial paralysis. Am J Ophthalmol. 2005;135:540
  111. Laccourreye O, Muscatelo L, Naude C. Botulinum toxin type A for Frey's syndrome: a preliminary prospective study. Ann Otol Rhinol Laryngol. 1998;107:52–55
  112. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21:121–125
  113. Lamanna C. The most poisonous poison. Science. 1959;130:763–772
  114. Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil. 2003;84(3 Suppl 1):S69–73[quiz S4–5]
  115. Larheim Ta , Westesson Pl , Sano T. Temporomandibular joint disk displacement: comparison in asymptomatic volunteers and patients. Radiology. 2001;218:428–432
  116. Laskawi R, Drobik C, Schonebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome). Laryngoscope. 1998;108:381–384
  117. Laskawi R, Rohrbach S, Rödel R, Surgical . Nonsurgical Treatment Options in Patients With Movement Disorders of the Platysma. J Oral Maxillofac Surg. 2002;60:157–162
  118. Lew MF, Adornato BT, Duane DD. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701–707
  119. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: Summary of three controlled clinical trials. Neurology. 2000;55(12 Suppl 5):S29–S35
  120. Lger G, Anthoy E, Brisse T. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006;81:1023–1028
  121. Liesegang TJ, Skuta GL, Cantor LB. Special forms of strabismus. In: Simon JW, Buckly EG, Drack AV, et al, (eds.) Pediatric Ophthalmology and Strabismus. San Francisco (CA): American Academy of Ophthalmology; 2004–2005. p. 140–41.
  122. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279–1281
  123. Lovely FW, Copeland RA. Reduction eminoplasty for chronic recurrent luxation of the temporomandibular joint. J Can Dent Assoc. 1981;3:179–184
  124. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: A double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol. 1996;35:569–572
  125. Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Moore D. Botulinum toxins types A and B for brow furrows: Preliminary experiences with type B toxin dosing. J Cosmet Laser Ther. 2002;4:15–18
  126. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized study. J Am Acad Dermatol. 2006;55:975–980
  127. Lowe PL, Patnaik R, Lowe NJ. A comparison of two botulinum type A toxin preparations for the treatment of glabellar lines: Double-blind, randomized, pilot study. Dermatol Surg. 2005;31:1651–1654
  128. Lundh H, Westesson PL. Clinical signs of temporomandibular joint internal derangement in adults. An epidemiologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1991;72:637–641
  129. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003;18:685–688
  130. Marchese-Ragona R, De Filippis C, Staffieri A. Parotid gland fistula: treatment with botulinum toxin. Plast Reconstr Surg. 2001;107:886–887
  131. Marchese-Ragona R, Galzignato PF, Marioni G. Endoscopic diagnosis of rhino-parotid fistula and successful treatment with botulinum toxin. Laryngoscope. 2005;115:2062–2064
  132. Marchese-Ragona R, Marioni G, Restivo AD. The role of botulinum toxin in postparotidectomy fistula treatment. A technical note. Am J Otolaryngol. 2006;27:221–224
  133. Marina S, Vasić M, Pekmezović T, Kostić V. Botulinum toxin in the treatment of sialorrhea. Abstracts Toxins/Toxicon 2008; 51: 50.
  134. Matarasso A, Matarasso SL, Brandt FS. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg. 1999;103:645–652
  135. Matarasso SL. Comparison of botulinum toxin types A and B: A bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg. 2003;29:7–13
  136. Mazow ML. Third cranial nerve palsy: Diagnosis and management strategies. In:  Rosenbaum AL,  Santiago AP editor. Clinical Strabismus Management: Principles and Surgical Technique. Philadelphia (PA): W.B. Saunders; 1999;p. 251–258
  137. Mckellar G, Lorentz I. The use of botulinum-toxin in the treatment of oromandibular dystonias and fractures of the mandibular condyle. Aust N Z J Med. 1992;22:428
  138. Metai M. Morphological and functional-changes in masseter after administration of botulinum toxin for treatment of masseteric hypertrophy. J Dent Res. 1996 May;75:1164
  139. Metz HS, Mazow M. Botulinum toxin treatment of acute sixth and third nerve palsy. Graefes Arch Clin Exp Ophthalmol. 1988;226:141–144
  140. Middlebrook JL, Franz DR. Botulinum toxins. In:  Sidell FR,  Takafuji ET,  Franz DR editor. Textbook of Military Medicine, Part I: Warfare, Weaponry, and the Casualty—Medical Aspects of Chemical and Biological Warfare. Washington, DC: Department of the Army, Office of The Surgeon General, Borden Institute; 1997;p. 643–654Chap 33
  141. Miller SC, Firestone JM. Psychosomatic factors in the aetiology of periodontal diseases. Am J Orthodont Oral Surg. 1947;33:675–680
  142. Montoya FJ, Riddell CE, Caesar R, Hague S. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye. 2002;16:705–709
  143. Moore AP, Wood CG. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A. Br Dent J. 1997;183:415–417
  144. Moore AP, Wood GD. The Medical Management of Masseteric Hypertrophy With Botulinum Toxin Type A. Br J Oral Maxillofac Surg. 1994;32:26–28
  145. Moreau MS, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. BOTOX in primary palmar hyperhidrosis. Br J Dermatol. 2003;149:1041–1045
  146. Niamtu J, Campbell RL. The anesthetic skin patch for topical cutaneous anesthesia. J Oral Maxillofac Surg. 1984;42:839–840
  147. Niamtu J. Aesthetic uses of botulinum toxin A. J Oral Maxillofac Surg. 1999;57:1228–1233
  148. Niamtu J. Botulinum Toxin A: A Review of 1,085 Oral and Maxillofacial Patient Treatments. J Oral Maxillofac Surg. 2003;61:317–324
  149. Niamtu J. Cosmetic facial surgery. Oral Maxillofac Surg Clin North Am. 2000;12:595
  150. O’day J. Use of botulinum toxin in neuro-opthalmology. Curr Opin Opthalmol. 2001;12:419–422
  151. Ohishi I. Oral toxicities of Clostridium botulinum type Aand Btoxins from different strains. Infect Immun. 1984;43:487–490
  152. Okeson JP. Orofacial Pain: Guidelines for Assessment, Diagnosis and Management. Chicago: Quintessence Co.; 1996;p. 45–52
  153. Ondo WG, Hunter C, Moore W. A double-blind placebocontrolled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62:37–40
  154. Padberg M, De Bruijn SF, De Haan RJ, Tavy DL. Treatment of chronic tension-type headache with botulinum toxin: a doubleblind, placebo-controlled clinical trial. Cephalalgia. 2004;24:675–680
  155. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology. 2000;54:244–247
  156. Pappert E, Leong M, Royal M. Botulinum toxin type B compared with type A in the treatment of patients with cervical dystonia: results from a randomized, double-blind non-inferiority study. Neurology. 2006;66(Suppl):A252
  157. Park YC, Lim JK, Lee DK, Yi SD. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci. 1993;8:334–340
  158. Pérez DM, Espiga PG. Recurrent Temporomandibular Joint Dislocation Treated With Botulinum Toxin: Report of 3 Cases. J Oral Maxillofac Surg. 2004;62:244–246
  159. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64:13–17
  160. Porta M, Gamba M, Bertacci G. Treatment of sialorrhea with ultrasound guided botulinum toxin type A injections in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 2001;70:538–540
  161. Quah BL, Ling YL, Cheong PY, Balakrishnan V. A review of 5 years’ experience in the use of botulinium toxin A in the treatment of sixth cranial nerve palsy at the Singapore National Eye Centre. Singapore Med J. 1999;40:405–409
  162. Racette BA, Good L, Sagitto S, Perlmutter JS. Botulinum toxin B reduces sialorrhea in Parkinsonism. Mov Disrod. 2003;18:1059–1061
  163. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg. 2002;126:459–467
  164. Ramirez OM, Maillard GF, Musolas A. The extended subperiosteal face lift: a definitive soft-tissue remodeling for facial rejuvenation. Plast Reconstr Surg 88:227–36, discussion 1991; 237–8.
  165. Redding GR, Rubright WC, Zimmerman SO. Incidence of brnxism. J Dent Res. 1966;45:1198–1204
  166. Relja M, Telarovic S. Botulinum toxin in tension-type headache. J Neurol. 2004;251(Suppl 1):I12–I14
  167. Restivo DA, Lanza S, Patti F. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology. 2002;59:1971–1973
  168. Rieder CR, Schestatsky P, Socal MP, Monte TL, Fricke D, Costa J. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007;30:39–42
  169. Riemann R, Pfennigsdorf S, Riemann E. Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland: a case report. Ophthalmology. 1999;106:2322–2324
  170. Rijsdijk BA. Botulinum toxin Type A treatment of cosmetically disturbing masseteric hypertrophy (DUT). Ned Tijdschr Geneeskd. 1998;142:529–532(Abstract)
  171. Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R. Treatment of tension-type headache with botulinum toxin type A: A double-blind, placebo-controlled study. Headache. 2000;40:300–305
  172. Rowe NL, Williams LI. Fracture of the zygomatic complex and orbit. In: 2nd edition.  Williams LI editors. Rowe and Williams’ Maxillofacial injuries. Vol. 1:Churchill Livingstone; 1994;p. 515
  173. Saad N, Lee J. The role of botulinum toxin in third nerve palsy. Aust N Z J Ophthalmol. 1992;20:121–127
  174. Sadick N. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles. Dermatol Surg. 2003;29:501–507
  175. Sadick NS. Botulinum toxin type B for glabellar wrinkles: A prospective open-label response study. Dermatol Surg. 2002;28:817–821
  176. Sadick NS, Matarasso SL. Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol Clin. 2004;22:221–226
  177. Sadiq SA, Downes RN. A clinical algorithm for the management of facial nerve palsy from an oculoplastic perspective. Eye. 1998;12(Pt 2):219–223
  178. Said SZ, Meshkinpour A, Carruthers A, Carruthers J. Botulinum toxin A: its expanding role in dermatology and esthetics. Am J Clin Dermatol. 2003;4:609–616
  179. Savarese R, Diamond M, Elovic E, Millis SR. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil. 2004;83:304–311
  180. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56:80–99
  181. Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache. 2001;41:658–664
  182. Schneider SA, Aggarwal A, Bhatt M, Dupont E, Tisch S, Limousin P. Severe tongue protrusion dystonia — clinical syndromes and possible treatment. Neurology. 2006;67:940–943
  183. Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain. 2004;109(1–2):110–114
  184. Schulte-Mattler WJ, Wieser T, Zierz S. Treatment of tensiontype headache with botulinum toxin: a pilot study. Eur J Med Res. 1999;4:183–186
  185. Schwaag S, Vollmer-Haase J, Rahman A, Frese A, Husstedt Iw , Evers S. Botulinum toxin A in the prophylactic treatment of migraine—a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24:838–843
  186. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc. 1981;79:734–770
  187. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924–927
  188. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 1988;3:333–335
  189. Scott KR, Kothari MJ, Venkatesh YS, Murphy T, Simmons Z. Parotid gland injections of botulinum toxin A are effective in treating sialorrhea in amyotrophic lateral sclerosis. J Clin Neuromuscul Dis. 2005;7:62–65
  190. Sen P, Papesch M. Botulinum Toxin A for the Management of Gustatory Sweating. Otolaryngol Head and Neck Surg. 2008;139:126
  191. Senno RG, Marciniak CM, Olsson AB, Esposito N, Duraski SA. Botulinum Toxin Type A in the Treatment of Temporomandibular Joint Dislocation in an Adult With Anoxic Brain Injury: A Case Report. (Abstract). Arch Phys Med Rehabil. 2003;84:E8
  192. Sessle BJ. Neural mechanisms and neuroplasticity related to deep craniofacial pain. Pain Forum. 1997;6:173–175
  193. Shaari CM. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope. 1991;101:960–963
  194. Shaari CM, Bei-Lian WU, Biller HF, Chuang S-K, Sanders I. Botulinum toxin decreases the salivation from canine submandibular glands. Otolaryngol Head Neck Surg. 1998;118:452–457
  195. Shorey CW, Campbell JH. Dislocation of the temporomandibular joint (Review). Oral Med Oral Pathol Oral Radiol Endod. 2000;89:662–668
  196. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40:445–450
  197. Smet-Dieleman H, Van De Heyning PH, Tassignon MJ. Botulinum A toxin injection in patients with facial nerve palsy. Acta Otorhinolaryngol Belg. 1993;47:359–363
  198. Smith HS, Audette J, Royal MA. Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain. 2002;18(suppl):S147–S154
  199. Smith LDS. The occurrence of Clostridium botulinum and Clostridium tetani in the soil of the United States. Health Lab Sci. 1978;15:74–80
  200. Sobel J, Tucker N, Sulka A. Foodborne botulism in the United States, 1900–2000. Emerg Infect Dis. 2004;10:1606–1611
  201. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007;13:253–260
  202. Spillane KS, Shelton JE, Hasty MF. Stroke-induced trismus in a pediatric patient: Long-term resolution with botulinum toxin A. Am J Phys Med Rehabil. 2003;82:485–488
  203. Stell R, Coleman R, Thompson P, Marsden CD. Botulinum toxin treatment of spasmodic torticollis. BMJ. 1988;297:616
  204. Stern RS. Clinical practice. Treatment of photoaging. N Engl J Med. 2004;350:1526–1534
  205. Stip E, Faughnan M, Desjardin I, Labrecque R. Botulinum toxin in a case of severe tardive dyskinesia mixed with dystonia. Br J Psychiatry. 1992;161:867–868
  206. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev. 1980;44:419–448
  207. Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope. 2002;112:73–81
  208. Svenson P. Pain mechanisms in myogenous temporomandibular disorders. Pain Forum. 1997;6:158–165
  209. Talarico-Filho S, Mendonça DO, Nascimento M, Sperandeo DE, Macedo F, Sanctis DE. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary Axillary hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No.):S44–S50
  210. Talebnejad MR, Sharifi M, Nowroozzadeh MH. The role of Botulinum toxin in management of acute traumatic third-nerve palsy. J AAPOS. 2008;12:510–513
  211. Tan EK, Fook-Chong S, Lum SY, Lim E. Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). J Neurol Sci. 2004;219(1–2):151–155
  212. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000;131:211–216
  213. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53:2102–2107
  214. Tan EK, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci. 2001;190:95–97
  215. Tang X, Wan X. Comparison of Botox with a Chinese type A botulinum toxin. Chin Med J (Engl). 2000;113:794–798
  216. Ting PT, Freiman A. The story of Clostridium botulinum: From food poisoning to BOTOX. Clin Med. 2004;4:258–261
  217. Titner R, Jankovic J. Botulinum toxin type A in the management of oromandibular dystonia and bruxism. In:  Brin MF,  Hallet M,  Jankovic J editor. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott: Williams and Wilkins; 2002;p. 343–356
  218. Tokuno T, Nakazawa K, Yoshida S, Matsumoto S, Shingu T, Sato S. Primary oculomotor nerve palsy due to head injury: analysis of 10 cases. No Shinkei Geka. 1995;23:497–501
  219. Truong DD, Hermanowicz N, Rontal M. Botulinum toxin in treatment of tardive dyskinetic syndrome. J Clin Psychopharmacol. 1990;10:438–439
  220. Truong DD, Jost WH. Botulinum toxin: Clinical use (Review). Parkinsonism and Related Disorders. 2006;12:331–355
  221. Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry. 1990;53:530
  222. Vargas H, Galatti LT, Parnes SM. A pilot study evaluationing the treatment of postparotidectomy sialoceles with botulinum toxin type A. Arch Otolaryngol Head Neck Surg. 2000;126:421–424
  223. Varma JK, Katsitadze G. Moiscrafishvili. Signs and symptoms predictive of death in patients with foodborne botulism—Republic of Georgia, 1980–2002. Clin Infect Dis. 2004;39:357–362
  224. Verma A, Steele J. Botulinum toxin improves sialorrhea and quality of living in bulbaramyotrophic lateral sclerosis. Muscle Nerve. 2006;34:235–237
  225. Von Lindern JJ, Niederhagen B, Berge S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61:774–778
  226. Watanabe Y, Bakheit A, Mclellan D. A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. Disabil Rehabil: Int Multidiscip J. 1998;20:62–65
  227. Widmer CG. Idiopathic masticatory muscle pain. Pain Forum. 1997;6:170–172
  228. Winterholler MG, Erbguth FJ, Wolf S, Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach [comment]. J Neurol Neurosurg Psychiatry. 2001;70:417–418
  229. Wohlfarth K, Muller C, Sassin I, Comes G, Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol. 2007;30:86–94
  230. Yao C-C, Chao C-H, Hong Y-K. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol. 2006;175:1158–1163
  231. Yasufuku-Takano J, Sakurai M, Kanazawa I, Nagaoka M. Successful treatment of intractable tardive dyskinesia with botulinum toxin. J Neurol Neurosurg Psychiatry. 1995;58:511–512
  232. Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992;15:1045–1049
  233. Zhibo X, Miaobo Z. Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar. J Plast Reconstr Aesthet Surg. 2008;61:1128–1129
  234. Zhibo X, Miaobo Z. Potential therapeutical effects of botulinum toxin type A in keloid management. Medical Hypotheses. 2008;71:623
  235. Ziegler CM, Haag C, Mühling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injections. Clin Oral Invest. 2003;7:52–55
  236. Zwart JA, Bovim G, Sand T, Sjaastad O. Tension headache: botulinum toxin paralysis of temporal muscles. Headache. 1994;34:458–462

PII: S0901-5027(09)01146-1

doi: 10.1016/j.ijom.2009.10.022

International Journal of Oral & Maxillofacial Surgery
Volume 39, Issue 3 , Pages 197-207 , March 2010

Article Tools